In adoptive T-cell transfer as an intervention for malignant diseases, retroviral transfer of T-cell receptor (TCR) genes derived from CD8 + cytotoxic T-lymphocyte (CTL) clones provides an opportunity to generate a large number of T cells with the same antigen specificity. We cloned the TCR-ab genes from a human leukocyte antigen (HLA)-A*2402-restricted CTL clone specific for MAGE-A4 143-151 . The TCR-ab genes were transduced to 99.2% of non-TCR expressing SupT1, a human T-cell line, and to 12.7-32.6% of polyclonally activated CD8 + T cells by retroviral transduction. As expected, TCR-ab gene-modified CD8
Introduction
There is a growing interest in immunotherapy for neoplastic diseases. [1] [2] [3] Among various approaches, adoptive T-cell transfer of in vitro cultured T cells derived from cancer patients with spontaneously developed immune responses proposes a potential strategy of immunotherapy by presenting obvious tumor regression in some trials. [4] [5] [6] However, limitation to obtain sufficient number of tumor antigen-specific T cells hampers the application of this approach to a large number of patients. 6, 7 To overcome this obstacle, several devices have been tested and one promising approach is genetic modification of peripheral blood mononuclear cells (PBMCs); namely transduction of the high affinity T-cell receptor (TCR) into nonspecific peripheral T cells obtained from patients. [6] [7] [8] [9] A recent report of the clinical trial showing that adoptive transfer of TCR-transduced cells by retrovirus has resulted in durable engraftment of 410% of peripheral blood lymphocytes (PBLs) for 2 months, is a milestone in this field. 4 However, there is little or no detailed information on the phenotypic, functional and genetic stability of the transduced TCR genes over several months. MAGE-A4 is a germ cell protein often expressed in cancer cells, but not in normal somatic cells. 10 In monitoring immune responses in patients with MAGE-A4-expressing cancers, MAGE-A4-specific CD4 + and CD8 + T-cell responses were clearly elicited in some of these patients, suggesting that MAGE-A4 is an immunogenic protein and a potential target for immunotherapy. 11, 12 We have recently reported a novel MAGE-A4 epitope bound to human leukocyte antigen (HLA) A*2402 by the use of a CD8 + T-cell clone 2-28. 12 This clone effectively killed tumor cell lines expressing both MAGE-A4 and HLA-A*2402. The ab TCR used in this clone recognized naturally processed MAGE-A4 antigen, namely useful for the preparation of T cells for adoptive T-cell therapy using retroviral TCR gene transfer. 12 In the present study, we isolated TCR-ab genes from this clone and examined whether PBMCs were efficiently transduced with the TCR by retroviral transduction. These TCR gene-transduced cells produced cytokines and exhibited cytotoxicity against MAGE-A4-expressing tumor cells on an ab TCR-dependent manner. We then generated 24 clones of CD8 + T cells from PBMCs transduced with the TCR and examined the long-term phenotypic, functional and genetic stability of transduced TCR kept in culture over 6 months.
Results and discussion

Construction of ab TCR-expressing retroviral vector and efficiency of transduction into T cells
We have established an HLA-A*2402-restricted MAGE-A4 143-151 -specific ab CD8 + cytotoxic T-lymphocyte (CTL) clone 2-28 as described previously 12 and TCR usage information was examined. TCR of this clone was composed of TCR-a V8-1 and TCR-b V7-9 (Supplementary Figure 1 ). Using the isolated TCR-a-and -b-chain cDNAs of this clone, we constructed MS-bPa, a retroviral vector harboring the a-and b-chain cDNAs. The constructs use the murine stem cell virus (MSCV) long terminal repeat (LTR) to drive the expression of b gene, while the a gene is controlled by an internal phosphoglycerate kinase (PGK) promoter (Figure 1a ). This retroviral vector was transduced into a human T-cell line SupT1, 13 and CD8 and TCR expressions were analyzed by flow cytometry. More than 95% of the cells expressed the transduced TCR (Figure 1b, Supplementary Figure 2 ). Next, we tested the efficiency of its transduction to PBMCs of healthy donors. Transduction of the retroviral vector to PBMCs was conducted twice on days 2 and 3 after polyclonal stimulation by anti-CD3 antibodies and cells were assessed for CD8 and TCR expression by flow cytometry. As shown in Figure 1c , 12.7-32.6% of polyclonally activated CD8 + T cells expressed retrovirally transduced ab TCR, indicating that this retroviral vector efficiently transduces ab TCR to PBMCs. It has recently been shown that CD4 + T cells are also successfully transduced with the TCR and these cells recognize antigen productively. 9, 14 In contrast to these reports, CD4 + T cells were not stained with MAGE-A4 143-151 / HLA-A*2402 tetramers without co-expression with CD8, suggesting that ab TCR used in our study was dependent on CD8 (Supplementary Figure 3) . The decreased TCR transduction efficiency from 99% in SupT1 cells to 12.7-32.6% in PBMCs may reflect the mispairing with endogenous TCR or more likely the differences of transduction efficacy to cell line or mixed population such as PBMCs. 
CD8
+ T-cell clones derived from retrovirally TCR-ab gene-modified PBMCs recognize target cells in a transduced TCR-dependent manner
To gain insight into the effector mechanism(s) by which retrovirally TCR-ab gene-modified PBMCs exhibited cytotoxicity, we generated CD8 + T-cell clones from retrovirally TCR gene-modified PBMCs by limiting dilution, and 24 clones with a wide range of the transduced TCR expression were established ( Table 1) . The difference of the transduced TCR expression level may reflect the characteristics of introduced or endogenous TCR, namely the intrinsic quality of each TCR rather than TCR transduction efficacy as reported previously. 15 Among these, we selected four clones with relatively higher transduced TCR expression based on the data of percentage and mean fluorescence intensity (Figure 2a , Table 1 ). Next, we stimulated CD8 + T-cell clones with transduced TCR expression by cognate or control peptide-loaded HLA-A*2402 + Epstein-Barr virus (EBV)-transformed B cells (EBV-B) and analyzed the production of various cytokines, including IFN-g, interleukin (IL)-4, IL-10, granulocyte monocyte-colony-stimulating factor (GM-CSF) and tumor necrosis factor (TNF)-a, and various effector molecules, for example, perforin and granzyme B. All clones examined produced IFN-g, GM-CSF, TNF-a, perforin and granzyme B, but not IL-4 or IL-10 ( Figure 2b ; data not shown), representing type I phenotype. The production of IFN-g and GM-CSF was confirmed with intracellular staining (Figure 2c ; data not shown). There is discrepancy in the number of IFN-g secreting cells and tetramer-positive cells. This may due to the detection limit of functional assay system and/or some cells may exhaust and lose the cytokine secretion capacity during the culture period. To determine whether these CD8 + T-cell clones also exhibit killing potential on a transduced TCR-dependent manner, they were cultured with cognate or control peptide-loaded HLA-A*2402 + EBV-B and cytotoxicity was analyzed with 51
Cr release assay. CD8 + T-cell clones killed cognate peptide-loaded EBV-B cells but not control peptideloaded EBV-B cells (Figure 2b ).
Transduced TCR-ab genes are phenotypically, functionally and genetically stable over 6 months
We next examined the stability of the transduced TCR using the established CD8 + T-cell clones. The transduced TCR expression in CD8 + T-cell clones was stable and maintained for more than 6 months when analyzed with MAGE-A4 143-151 /HLA-A*2402 tetramers (Figure 2d ). We also examined the function of these CD8 + T-cell clones with enzyme-linked immunosorbent assay (ELISA) and 51 Cr release assay and confirmed the antigen-specific cytokine production and cytotoxicity (Figures 2b and c) . Furthermore, sequencing of the TCR cDNA independently prepared from four different CD8 + T-cell clones generated from retrovirally TCR gene-modified PBMCs showed no mutations or conversions (Supplementary Figure 4) . Taken together, these results indicate that retrovirally transduced TCR genes are stably kept and functional over 6 months.
Using Va and Vb TCR usage information of the MAGE-A4 143-151 -specific ab CD8 + CTL clone, we generated MS-bPa, a retroviral vector harboring the a-and b-chain cDNAs. The transduction efficacy of this vector examined with tetramer staining was better or as well as that described previously. 8, 9 These TCR-ab gene-modified PBMCs recognized not only MAGE-A4 143-151 peptide-pulsed T2-A*2402 but also tumor cell lines expressing MAGE-A4 and HLA-A*2402. It has been reported that antigen-specific T cells induced by peptide vaccination could neither recognize naturally processed antigens nor kill tumor cells in a similar cancer/testis antigen NY-ESO-1 system since peptide vaccine-induced T cells possess relatively low affinity TCR compared to spontaneously induced antigen-specific T cells. 16, 17 The 1  197  21  2  232  25  8  448  65  12  249  32  13  357  32  14  321  48  21  258  33  22  1156  93  23  467  45  24  489  64  26  188  18  29  559  73  30  415  45  31  514  65  37  1208  86  39  735  64  42  1732  92  44  768  79  48  704  77  50  1027  77  51  724  80  52  302  46  53  332  49  54  324  45 Abbreviation: MFI, mean fluorescence intensity.
Stable MAGE-A-specific ab TCR-transduced T cells A Hiasa et al MAGE-A4 143-151 -specific CD8 + CTL clone used in this study was established from a patient with a MAGE-A4-expressing head and neck cancer, which showed spontaneous immune responses and recognized naturally processed MAGE-A4 antigen. 12 These data suggest that TCR-a V8-1 and TCR-b V7-9 identified from MAGE-A4 143-151 -specific CD8 + CTL clone is high affinity and advantageous with respect to clinical application of TCR-ab gene-modified PBMCs.
A unique finding in our study is that we established 24 clones of CD8 + CTL from retrovirally TCR gene-modified PBMCs, and that these CD8 + CTL clones had phenotypically, genetically and functionally stable transduced TCR over 6 months. In this regard, a recent study reported adoptive transfer of retrovirally tumor antigenspecific TCR-transduced CD8 + T cells that were functional over more than 1 year in some patients. 4 Interestingly, there were discordance in the persistence of transduced cells when measured by PCR compared to measurement by Vb-expressing cells and tetramer-binding cells. 4 It is possible that the discordance may reflect in part mispairing of transduced TCR chains with the endogenous chains as well as differences in the sensitivity of each assay. 4 While these are plausible explanations, our data still demonstrate that retrovirally transduced TCR are phenotypically, functional and genetically stable for more than 6 months, indicating that this strategy could be applicable to raise a sufficient number of tumorspecific T cells for adoptive T-cell transfer in patients with limited tumor-specific lymphocytes. #14 #37  #51  #48   #14 #37  #51  #48   #14 #37  #51  #48  #14 #37  #51  #48   #14 #37  #51  #48  #14 #37  #51  #48   day 
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